|This Slide: #78 of 83|
Slide #78. BioCryst Pharmaceuticals, Inc. — Presidio Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Presidio Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. and privately held Presidio Pharmaceuticals, Inc. today announced that the companies have signed a definitive merger agreement for Presidio to be acquired by BioCryst in an all-stock transaction. The transaction has been approved by the Boards of both companies. The transaction values Presidio at approximately $101 million, based on yesterday's closing BioCryst share price of $4.11 per share. The transaction is expected to close in the first quarter of 2013, and is subject to customary conditions, including approval by BioCryst shareholders.
BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
BCRX SEC Filing Email Alerts Service
Open the BCRX Page at The Online Investor »
Free BCRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Buy (3.20 out of 4)